LS CancerDiag Rebrands to Lynsight

About Lynsight

Lynsight provides reliable Lynch syndrome diagnotics through our functional test, DiagMMR. Our mission is to empower families and healthcare professionals to make better-informed decisions for cancer prevention.  

Our Values

Respecting healthy life

We empower individuals to make informed decisions about their health through our innovative Lynch syndrome testing method, DiagMMR.

Creating & sharing knowledge

We are dedicated to advancing medical science by continuously generating and disseminating vital information about Lynch syndrome.

Committing to trust & quality

Lynsight is committed to upholding the highest standards of trust and quality, ensuring reliability and transparency with our stakeholders and partners.
Group 164

Founded by the leaders
in Lynch syndrome research

Lynsight has been on the forefront of Lynch syndrome research for over 10 years, driven by the mission to find a better way to help people prevent cancer. What started in the labs of the University of Helsinki in the 1990s will not stop until every potential Lynch syndrome case is tested every year.

Bringing preventative care to

more families

Every Lynch syndrome case that remains unclear is an entire family that could be missing out on life saving cancer preventative strategies. Lynsight is dedicated to making sure these families become known and cared for by testing for Lynch syndrome early.

ABOUT LYNCH
SYNDROME

Lynch syndrome is the main cause of hereditary cancers with a broad spectrum of tumors, the most prominent being colorectal and endometrial cancers. With an estimated 1 in 300 people of the world’s population being affected by Lynch syndrome, there are millions of people at a very increased risk for cancer.

Founding Year

Lynsight is founded (as LS CancerDiag) as a spin-off from the University of Helsinki, also thanks to an ERC grant.

2013

First Patent Granted

Australia is the first country to grant the patent to Lynsight for the DiagMMR innovation.

2015

First Validation Study

A first clinical study is launched to validate DiagMMR in collaboration with the central hospitals of Helsinki and Jyväskylä.

2016

Validation Study Results

The validation study is complete with excellent accuracy results.

2018

Domestic Market Launch

DiagMMR obtains the CE mark and is launched into the Finnish market (ceased in 2023).

2019

International Attention

Lynsight is selected for various accelerator programmes across Europe to support the new phase of growth.

2020

ISO Certification

Lynsight's Quality Management System is certified according to the international ISO 13485 standard for medical devices.

2022

Fundraising of €5.4M

Lynsight successfully raises funds in record time to establish operations in the US and fuel the growth ambitions into this key market.

 

2023

Strategic Rebrand

Lynsight rebrands itself in preparation for the strategic priority of entering the US market.

2024

Group 164

The future of


Lynch syndrome testing

Lynsight’s purpose is to improve global health outcomes by providing reliable diagnostics for Lynch syndrome and promoting awareness about hereditary cancer risks. With a commitment to pushing the boundaries of scientific discovery, we’re leading the way toward a future where Lynch syndrome testing is not only more accessible but also more precise and impactful.

Join us as we pave the path to a brighter future in Lynch syndrome diagnostics.

About Lynsight

Lynsight provides reliable Lynch syndrome diagnotics through our functional test, DiagMMR. Our mission is to empower families and healthcare professionals to make better-informed decisions for cancer prevention.  

Our Values

Respecting healthy life

We empower individuals to make informed decisions about their health through our innovative Lynch syndrome testing method, DiagMMR.

Creating & sharing knowledge

We are dedicated to advancing medical science by continuously generating and disseminating vital information about Lynch syndrome.

Committing to trust & quality

Lynsight is committed to upholding the highest standards of trust and quality, ensuring reliability and transparency with our stakeholders and partners.
Group 164

Founded by the leaders
in Lynch syndrome research

Lynsight has been on the forefront of Lynch syndrome research for over 10 years, driven by the mission to find a better way to help people prevent cancer. What started in the labs of the University of Helsinki in the 1990s will not stop until every potential Lynch syndrome case is tested every year.

Bringing preventative care to

more families

Every Lynch syndrome case that remains unclear is an entire family that could be missing out on life saving cancer preventative strategies. Lynsight is dedicated to making sure these families become known and cared for by testing for Lynch syndrome early.

ABOUT LYNCH
SYNDROME

Lynch syndrome is the main cause of hereditary cancers with a broad spectrum of tumors, the most prominent being colorectal and endometrial cancers. With an estimated 1 in 300 people of the world’s population being affected by Lynch syndrome, there are millions of people at a very increased risk for cancer.

Founding Year

Lynsight is founded (as LS CancerDiag) as a spin-off from the University of Helsinki, also thanks to an ERC grant.

2013

First Patent Granted

Australia is the first country to grant the patent to Lynsight for the DiagMMR innovation.

2015

First Validation Study

A first clinical study is launched to validate DiagMMR in collaboration with the central hospitals of Helsinki and Jyväskylä.

2016

Validation Study Results

The validation study is complete with excellent accuracy results.

2018

Domestic Market Launch

DiagMMR obtains the CE mark and is launched into the Finnish market (ceased in 2023).

2019

International Attention

Lynsight is selected for various accelerator programmes across Europe to support the new phase of growth.

2020

ISO Certification

Lynsight's Quality Management System is certified according to the international ISO 13485 standard for medical devices.

2022

Fundraising of €5.4M

Lynsight successfully raises funds in record time to establish operations in the US and fuel the growth ambitions into this key market.

 

2023

Strategic Rebrand

Lynsight rebrands itself in preparation for the strategic priority of entering the US market.

2024

Group 164

The future of


Lynch syndrome testing

Lynsight’s purpose is to improve global health outcomes by providing reliable diagnostics for Lynch syndrome and promoting awareness about hereditary cancer risks. With a commitment to pushing the boundaries of scientific discovery, we’re leading the way toward a future where Lynch syndrome testing is not only more accessible but also more precise and impactful.

Join us as we pave the path to a brighter future in Lynch syndrome diagnostics.